NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $308.32 million. The enterprise value is $317.70 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 33.08 million shares outstanding. The number of shares has increased by 12.50% in one year.
| Current Share Class | 33.08M |
| Shares Outstanding | 33.08M |
| Shares Change (YoY) | +12.50% |
| Shares Change (QoQ) | +4.39% |
| Owned by Insiders (%) | 3.62% |
| Owned by Institutions (%) | 59.22% |
| Float | 21.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.25 |
| Forward PS | 2.96 |
| PB Ratio | 15.84 |
| P/TBV Ratio | 15.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.47, with a Debt / Equity ratio of 3.68.
| Current Ratio | 5.47 |
| Quick Ratio | 4.42 |
| Debt / Equity | 3.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.31 |
Financial Efficiency
Return on equity (ROE) is -176.94% and return on invested capital (ROIC) is -14.23%.
| Return on Equity (ROE) | -176.94% |
| Return on Assets (ROA) | -12.39% |
| Return on Invested Capital (ROIC) | -14.23% |
| Return on Capital Employed (ROCE) | -22.33% |
| Revenue Per Employee | $481,359 |
| Profits Per Employee | -$140,989 |
| Employee Count | 184 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.07% in the last 52 weeks. The beta is 1.90, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 1.90 |
| 52-Week Price Change | +35.07% |
| 50-Day Moving Average | 10.21 |
| 200-Day Moving Average | 11.31 |
| Relative Strength Index (RSI) | 48.59 |
| Average Volume (20 Days) | 198,761 |
Short Selling Information
The latest short interest is 1.11 million, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 1.11M |
| Short Previous Month | 896,542 |
| Short % of Shares Out | 3.35% |
| Short % of Float | 5.13% |
| Short Ratio (days to cover) | 4.81 |
Income Statement
In the last 12 months, NeuroPace had revenue of $88.57 million and -$25.94 million in losses. Loss per share was -$0.84.
| Revenue | 88.57M |
| Gross Profit | 67.08M |
| Operating Income | -19.87M |
| Pretax Income | -31.51M |
| Net Income | -25.94M |
| EBITDA | -19.66M |
| EBIT | -19.87M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $62.14 million in cash and $71.52 million in debt, giving a net cash position of -$9.38 million or -$0.28 per share.
| Cash & Cash Equivalents | 62.14M |
| Total Debt | 71.52M |
| Net Cash | -9.38M |
| Net Cash Per Share | -$0.28 |
| Equity (Book Value) | 19.44M |
| Book Value Per Share | 0.59 |
| Working Capital | 76.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.09 million and capital expenditures -$344,000, giving a free cash flow of -$16.43 million.
| Operating Cash Flow | -16.09M |
| Capital Expenditures | -344,000 |
| Free Cash Flow | -16.43M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
Gross margin is 75.74%, with operating and profit margins of -22.43% and -29.29%.
| Gross Margin | 75.74% |
| Operating Margin | -22.43% |
| Pretax Margin | -29.29% |
| Profit Margin | -29.29% |
| EBITDA Margin | -22.20% |
| EBIT Margin | -22.43% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.50% |
| Shareholder Yield | -12.50% |
| Earnings Yield | -8.41% |
| FCF Yield | -5.33% |
Analyst Forecast
The average price target for NeuroPace is $16.67, which is 78.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.67 |
| Price Target Difference | 78.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 19.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.95 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.95 |
| Piotroski F-Score | 4 |